Tasimelteon
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-([(1R,2R)-2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 609799-22-6 |
| ATC code | None |
| PubChem | CID 10220503 |
| UNII | SHS4PU80D9  |
| Chemical data | |
| Formula | C15H19NO2 |
| Mol. mass | 245.3 g/mol |
|
|
 (what is this?) (verify) |
|
Tasimelteon (BMS-214,778) is a drug which is under development for the treatment of insomnia and other sleep disorders.[1] It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to older drugs such as ramelteon.[2] It has been through Phase III trials successfully and was shown to improve both onset and maintenance of sleep, with few side effects.[3]
A year-long (2011-2012) study at Harvard is testing the use of tasimelteon in blind subjects with non-24-hour sleep-wake disorder.[4]
[edit] See also
Discovery and development of melatonin receptor agonists
[edit] References
- ^ 'Time-bending drug' for jet lag. BBC News. 2 December 2008
- ^ Vachharajani, Nimish N., Yeleswaram, Krishnaswamy, Boulton, David W. (April 2003). "Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist". Journal of Pharmaceutical Sciences 92 (4): 760–72. doi:10.1002/jps.10348. PMID 12661062.
- ^ Shantha MW Rajaratnam, Mihael H Polymeropoulos, Dennis M Fisher, Thomas Roth, Christin Scott, Gunther Birznieks, Elizabeth B Klerman (2009-02-07). "Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials". The Lancet 373 (9662): 482–491. doi:10.1016/S0140-6736(08)61812-7. PMID 19054552. Retrieved 2010-02-23.
- ^ Audio interview with Joseph Hull of Harvard, spring 2011
|
|||||||||||||||||||||||||||||||
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
